Back to Treasuries

ATAI Life Sciences BV

#115 in public ATAI.US public

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada.

Bitcoin Holdings

Total Bitcoin â‚¿ 58 BTC
% of 21M Supply 0.0%
Current Value $4,445,470
Cost Basis $5,000,000
ROI -11.09%
% of Company 0.3%
mNAV 305.93x
BTC/Share â‚¿ 0.00000036 BTC
Market Cap $1,590,480,128
Enterprise Value $1,590,790,128
Latest Purchase Mar 31, 2025
Avg. cost / BTC $86,207

ATAI Life Sciences BV Stock Priced in BTC

0.000057 BTC

ATAI Life Sciences BV Bitcoin Holdings Over Time

â‚¿ 58 BTC

Bitcoin Acquisitions History

Type BTC Change Holdings Transaction Value Date
Buy +0 BTC 0 BTC $0 —
Buy +0 BTC 0 BTC $0 —
Buy +0 BTC 0 BTC $0 —
Buy +0 BTC 0 BTC $0 —
Buy +0 BTC 0 BTC $0 —

Get instant access to full data

Register for free

Financial Highlights

Revenue (TTM) $3,488,000
Profit Margin 0%
Operating Margin -3239.1%
ROE -378.0%
Analyst Rating 100% Buy (7 analysts)
Target Price $14
ROA -33.04%
EPS $-2.84
Book Value $0.556
Target Price $14
Current Volume 5,015,800
Avg Volume (30d) 6,682,610
Volume vs Avg 0.75x

ATAI Life Sciences BV Stock Price vs Bitcoin

$4.32 / $76,646

Company Overview

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.

Sector Healthcare
Industry Biotechnology
Sub-Industry Biotechnology
Employees 99
Exchange NASDAQ
Fiscal Year End December
IPO Date June 2021
Website Visit Website

Stock Returns

Share Price $4.32
1W Return +7.6%
1M Return -9.43%
3M Return +8.82%
1Y Return +126.18%
1Y vs BTC +160.1%
52W High $6.75
% Down from 52W High -36.0%

Key Executives

Mr. Christian Angermayer Co-Founder & Chairman of the Board
Age: 48
Dr. Srinivas G. Rao M.D., Ph.D. Co-Founder, CEO & Executive Director
Age: 57
Dr. Gerd G. Kochendoerfer Ph.D. Chief Operating Officer
Age: 58
Mr. Ryan Barrett J.D. Chief Legal & Business Officer
Age: 45
Mr. Michael Eric Faerm Chief Financial Officer
Age: 59
Ms. Anne Johnson CPA Chief Accounting Officer
Age: 57
Dr. Glenn Short Ph.D. Chief Scientific Officer
Age: 56
Dr. Jason Awe Ph.D. Vice President of Investor Relations
Age: 2026

Company Details

Address 250 West 34th Street, New York, NY, United States, 10119
Phone 332 282 0507
ISIN NL0015000DX5
CIK 0001840904
Currency USD
Most Recent Quarter 2026-03-31

Growth Metrics

Earnings Growth (YoY) -96.8%
Revenue Growth (YoY) -38.7%

Balance Sheet (Q1 2026)

Total Assets $264,877,000
Total Liabilities $66,098,000
Total Equity $198,683,000
Cash & Equivalents $0
Total Debt $310,000
Current Assets $250,066,000
Current Liabilities $24,964,000
Long-term Debt $0

Additional Financials

EBITDA -$120,710,000
Gross Profit -$44,120,000
Revenue per Share $0.013
Diluted EPS (TTM) $-2.84
Outstanding Shares 160,000,000

EPS Estimates

Current Quarter $-0.1119
Current Year $-0.432
Next Quarter $-0.1032
Next Year $-0.4551

Recent Insider Activity

Name Title Type Shares Price Value Date SEC
Kevin James Craig INSIDER Sell 42,579 $5.00 $212,895 Apr 20, 2026

Get instant access to full data

Register for free

Major Holders

Major Institutional Holders
UBS Group AG
2.0241%
3,238,560 shares
ARK Investment Management LLC
0.901%
1,441,600 shares
Candriam Luxembourg S.C.A.
0.8412%
1,345,920 shares
Marshall Wace Asset Management Ltd
0.7291%
1,166,560 shares
RTW INVESTMENTS, LLC
0.5451%
872,160 shares
Ally Bridge Group (NY) LLC
0.4669%
747,040 shares
Eagle Health Investments LP
0.4659%
745,440 shares
Sumitomo Mitsui Trust Group Inc
0.1547%
247,520 shares
Northern Trust Corp
0.1466%
234,560 shares
T. Rowe Price Associates, Inc.
0.1268%
202,880 shares
Major Mutual Fund Holders
Vanguard Total Stock Mkt Idx Inv
2.5621%
4,099,360 shares
ARK Genomic Revolution ETF
1.2064%
1,930,240 shares
ARK Genomic Revolution
1.1335%
1,813,600 shares
Vanguard Institutional Extnd Mkt Idx Tr
0.5926%
948,160 shares
iShares Biotechnology ETF
0.5911%
945,760 shares
Candriam Eqs L Biotech C USD Cap
0.4737%
757,920 shares
HBM Healthcare Investments AG Ord
0.4129%
660,640 shares
Fidelity Extended Market Index
0.2827%
452,320 shares
First Trust Small Cap Gr AlphaDEX® ETF
0.2673%
427,680 shares
Schwab US Small-Cap ETFâ„¢
0.2558%
409,280 shares

Frequently Asked Questions

Common questions about ATAI Life Sciences BV's Bitcoin holdings

How much Bitcoin does ATAI Life Sciences BV hold?

ATAI Life Sciences BV currently holds 58 BTC, which represents 0.0% of the total Bitcoin supply (21 million). This makes them the 115th largest public Bitcoin holder.

What is the current value of ATAI Life Sciences BV's Bitcoin holdings?

As of today, ATAI Life Sciences BV's Bitcoin holdings are worth approximately $4,445,470. This represents 0.3% of the company's total market value.

What is ATAI Life Sciences BV's average cost basis for Bitcoin?

ATAI Life Sciences BV's average cost basis for their Bitcoin purchases is $5,000,000 per Bitcoin. Their current return on investment (ROI) is -11.09%.

When did ATAI Life Sciences BV last buy Bitcoin?

ATAI Life Sciences BV's most recent Bitcoin purchase was Mar 31, 2025. View purchase details

What type of company is ATAI Life Sciences BV?

ATAI Life Sciences BV is a public company in the Healthcare sector and Biotechnology industry with approximately 99 employees .

What is ATAI Life Sciences BV's market capitalization?

ATAI Life Sciences BV has a market capitalization of approximately $1,590,480,128 and annual revenue of $3,488,000 .

What is ATAI Life Sciences BV's mNAV?

ATAI Life Sciences BV's mNAV (Market-to-Net Asset Value) is 305.93x, comparing the company's market value to its Bitcoin holdings value. An mNAV of 1.0 means market value equals Bitcoin stash, while >1.0 indicates a premium for the company's Bitcoin strategy.

What is ATAI Life Sciences BV's market cap and enterprise value?

ATAI Life Sciences BV has a market capitalization of $1,590,480,128 and an enterprise value of $1,590,790,128. Enterprise value represents the total company value including debt and cash, providing a more complete valuation picture than market cap alone.

Other public Companies

Similar companies with Bitcoin treasury holdings

RSXYZ Public Company Limited

XYZ.BK

Holdings 74.97 BTC
Value $5,746,154
ROI -11.07%

Figma, Inc.

FIG

Holdings 842.6 BTC
Value $64,581,953
ROI -29.03%

BTC-B.SE

BTC-B.SE

Holdings 167.33 BTC
Value $12,825,182
ROI 422.64%

Core Scientific, Inc.

CORZ

Holdings 613 BTC
Value $46,984,023
ROI -86.34%

Block, Inc

XYZ

Holdings 8,997.89 BTC
Value $689,652,637
ROI 120.57%
Newhedge
© 2026 Newhedge. All Rights Reserved.

Chat

You are commenting as a guest. .

alon

Hey @trader, which data isn't updating? Are you talking about the website speed?

Comment from Bitcoin Dashboard

trader

Please why are the data's on newhedge taking so long to updates? I mean hours

Comment from Bitcoin Dashboard

G
Guest
radicalsound277

correct horse battery staple

Comment from Bitcoin Dashboard

G
Guest
sharputxo635

Plain brown wrapper grand forks

Comment from Bitcoin vs Gold Correlation

23 May 2026

G
Guest
radicalhardmoney456

hi

Comment from Bitcoin Dashboard

alon

:)

Comment from Bitcoin Dashboard

G
Guest
silenthodl877

Exchange reserve data! thank you

Comment from Bitcoin Exchange Reserves

G
Guest
peerlessimmutableledger591

Ship captains

Comment from Bitcoin Dashboard

maisonmargiela

Saylor and the ETFs

Comment from Bitcoin Dashboard

G
Guest
autonomousbitcoin141

who is buying?

Comment from Bitcoin Activity Rate

20 May 2026

yousifsamad07

ok

Comment from Bitcoin Total Node Distribution Map

bittynakamoto

I haven't seen a single Saylor tweet about anything defi or ethereum related

19 May 2026

G
Guest
braveselfcustody296

Michael Saylor has been reposting links to DeFi scams built on Ethereum, presumably because they are providing demand for his perpetual preferred stock STRC. As Saylor himself notes, 80% of STRC is owned by retail investors, which makes promoting these DeFi ponzis even more irre

Comment from Bitcoin Dashboard

G
Guest
braveselfcustody296

Saylor is now promoting Ship coins wowwww

Comment from Bitcoin Dashboard

drenchravine

who thinks the Hormuz Bitcoin toll will affect price?

G
Guest
anarchicseed970

apa itu devalusi rupiah

Comment from Bitcoin MVRV Ratio

G
Guest
strongpeer126

gg

Comment from Bitcoin Dashboard

18 May 2026

G
Guest
resistantuncensorable206

When a lot of people buy, the price goes up. If more people start selling than buying, the price goes down

Comment from Bitcoin Dashboard

G
Guest
strongorangepill639

How does this work

Comment from Bitcoin Reachable Node Distribution Live Map

17 May 2026

G
Guest
wildproofwork486

Good write-up. I definitely love this website. Continue the good work!